Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - calcitonin, salmon - nasal spray solution - 100 international unit

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - calcitonin, salmon - nasal spray solution - 200 international unit

Ισραήλ - Αγγλικά - Ministry of Health

genmedix , israel - calcitonin salmon; calcitonin salmon - solution for injection - calcitonin salmon 100 iu/ml; calcitonin salmon 100 iu/ml - calcitonin (salmon synthetic) - calcitonin (salmon synthetic) - calcitonin is indicated for:• prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures.• for the treatment of paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment.• treatment of hypercalcemia of malignancy. calcitonin is indicated for:• prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures.• for the treatment of paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment.• treatment of hypercalcemia of malignancy.

Ινδία - Αγγλικά - Central Drugs Standard Control Organization

novartis - calcitonin - nasal spray - 2200iu.(salmon) - 2ml

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - salcatonin 200 [iu] (plus 5% overage);   - solution for inhalation - 200 iu - active: salcatonin 200 [iu] (plus 5% overage)   excipient: benzalkonium chloride hydrochloric acid purified water sodium chloride

Ισραήλ - Αγγλικά - Ministry of Health

novartis pharma services ag - calcitonin salmon 2200 iu/ml - solution - calcitonin (salmon synthetic) - bone pain associated with osteolysis due to malignancies. paget's disease of bone only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. neurodystrophic disorders.

Αίγυπτος - Αγγλικά - EDA (Egyptian Drug Authority)

novartis pharma egypt - nasal spray - 50 i.u.

Αίγυπτος - Αγγλικά - EDA (Egyptian Drug Authority)

novartis pharma egypt - nasal spray - 100 i.u.

Αίγυπτος - Αγγλικά - EDA (Egyptian Drug Authority)

novartis pharma egypt - nasal spray - 200 i.u./ml

Αίγυπτος - Αγγλικά - EDA (Egyptian Drug Authority)

novartis pharma egypt - nasal spray - 200 i.u./ml